Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 28, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/28/17 - "Antibody Drug Conjugates" in Patent Application Approval Process (USPTO 20170190736)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Miao, Zhenwei; Chen, Gang; Zhu, Tong; Khasanov, Alisher B.; Deng, Dylan; Zhang, Hong, filed on January 28, 2016, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent ap
7/28/17 - "Apparatuses for Securing Components of a Drug Delivery System during Transport and Methods of Using Same" in Patent Application Approval Process...
"Apparatuses for Securing Components of a Drug Delivery System during Transport and Methods of Using Same" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors CABIRI, Oz; FILMAN, Reuven Y.; BAR-EL, Yossi, filed on March 17, 2017, was made available online on July 13, 2017
7/28/17 - "Contrast Agents for Magnetic Resonance Imaging" in Patent Application Approval Process (USPTO 20170189559)
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventor Lascola, Christopher David, filed on March 17, 2017, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. In the U.S., all nine FDA- approved MRI contrast agents are Gd-
7/28/17 - A strong 2Q for Merck, outlook mixed
Still, the maker of blockbuster Januvia for type 2 diabetes and advanced cancer drug Keytruda trimmed its 2017 profit expectations, citing the cost of a major new cancer drug partnership with AstraZeneca and a cyberattack last month. Merck& Co. reported second-quarter net income of $1.95 billion, or 71 cents per share, up from $1.21 billion, or 43
7/28/17 - Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug...
By a News Reporter-Staff News Editor at Drug Week Although 10 new opioid products with abuse-deterrent formulations have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the Tufts Center for the Study of Drug Deve
7/28/17 - Abzena and OBI Pharma Sign ThioBridge? Licence Agreement
By a News Reporter-Staff News Editor at Drug Week Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company.
7/28/17 - Agile Therapeutics Reports Second Quarter 2017 Financial Results
Agile Therapeutics, Inc., a women's healthcare company today reported financial results for the three and six months ended June 30, 2017, and provided a corporate update for the second quarter 2017.. On July 27, 2017, the Company announced that the FDA had acknowledged the resubmitted NDA for Twirla as a complete response to the CRL, and provided
7/28/17 - Alexion Posts Strong Second Quarter; Takes New Research Direction [The Hartford Courant]
July 28 Alexion Pharmaceuticals Inc. on Thursday posted sharply higher second-quarter profits and announced a shift in research and development to focus more on metabolic disorders and other illnesses. The New Haven- based biopharmaceutical company that markets rare-disease drugs posted revenue of $912 million, up 21 percent from the second quart
7/28/17 - Allergan Lends Support to Broaden Uterine Fibroid Awareness Month
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc announced its support of the White Dress Project and its efforts to expand uterine fibroid education and awareness. Led by The White Dress Project, efforts are underway to expand Fibroid Awareness throughout the U.S., with the ultimate goal of having it become a national o
7/28/17 - An Application for the Trademark "AVONEX" Has Been Filed by Biogen Idec MA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for " AVONEX" by Brenda Campbell, Paralegal, representing Biogen Idec MA. This application was made available to the public on July 11, 2017. The mark consists of the word' A
7/28/17 - Arbutus Biopharma Corp. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Jul. 10, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on July 10, 2017. The SEC file number is 0000903423-17-000461.. A U.S. Securities and Exchange Commission filing is a formal
7/28/17 - AstraZeneca and Merck establish strategic oncology collaboration
AstraZeneca and Merck will independently develop and commercialise Lynparza and potential medicine selumetinib in combinations with companies' respective PD-L1/PD-1 immuno-oncology medicines Imfinzi and Keytruda. Collaboration will significantly expand the potential of Lynparza, the world's first and leading PARP inhibitor, as a backbone of...
7/28/17 - Baxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio
DEERFIELD, Ill.,- Baxter International Inc., a global medical products company, today announced the completion of the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company. "The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost generic injectables and strengthen our
7/28/17 - Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020
*Second-Quarter GAAP Earnings Per Share of $0.48; Adjusted EPS of $0.63 Increased 37 Percent. *Raises Full-Year 2017 GAAP EPS to $1.85 to $1.95; Adjusted EPS to $2.34 to $2.40. DEERFIELD, Ill.,- Baxter International Inc. today reported results for the second quarter of 2017 and increased its financial outlook for full-year 2017 and 2020..
7/28/17 - Benitec Biopharma Ltd Files SEC Form EFFECT, Notice of Effectiveness (Jul. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Benitec Biopharma Ltd was posted on July 6, 2017. The SEC file number is. A U.S. Securities and Exchange Commission filing is a formal document or financial sta
7/28/17 - Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA [Sudan Tribune]
The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.- marketed formulation of Humira* 40 mg/0. 8 mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. BI 695501 has been accepted for regulatory review by the European Medicines Agency and th
7/28/17 - Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR NECTAR (barium sulfate) Oral Suspension
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced the U.S. Food and Drug Administration approved VARIBAR NECTAR oral suspension for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and p
7/28/17 - BREAKING: McCaskill Opioid Investigation Expands to Include Distributors and Additional Manufacturers
Claire McCaskill, D- Mo., ranking Democratic member of the Senate Homeland Security and Governmental Affairs Committee, issued the following news release:. McCaskill's newest requests for documents and information from opioid manufacturers were sent to Mallinckrodt, Endo, Teva, and Allergan, while a request to McKesson Corporation, AmerisourceBerge
7/28/17 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Jul. 10, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on July 10, 2017. The SEC file number is 0001213900-17-007309.. A U.S. Securities and Exchange Commission filing is a formal
7/28/17 - Corporate News Blog - Sensus Healthcare Announces Achievement of Approval from China's FDA for SRT-100, the Non-Invasive Superficial Radiation Therapy
LONDON, UK/ ACCESSWIRE/ July 28, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sensus Healthcare, Inc., following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/? Sensus operates in China through its partner, Chindex Medical Limited, a
7/28/17 - Cosmo Half-Year Report 2017
Dublin, Ireland- 28 July 2017- Cosmo Pharmaceuticals N.V. reports half-year results for the period ended 30 June 2017. Expansion of organization to commercialize products in the US progressed with the addition of further personnel with strong sales and marketing experience LuMeBlue NDA submitted to the FDA on 21 July 2017 Zemcolo NDA under preparat
7/28/17 - Data from Office of Generic Drugs Advance Knowledge in Coumarins and Indandiones (Integrating In Vitro, Modeling, and In Vivo Approaches to...
Financial support for this research came from U.S. Food and Drug Administration. The news reporters obtained a quote from the research from the Office of Generic Drugs, "Sensitivity analyses indicated that warfarin pharmacokinetics was not sensitive to solubility, particle size, density, or dissolution rate in pH 4.5, but was affected by dissolutio
7/28/17 - District Court Enters Permanent Injunction Against Tennessee Company and Its CEO to Stop Distribution of Unapproved and Misbranded Drugs
The U.S. District Court for the Eastern District of Tennessee entered a consent decree of permanent injunction against Crown Laboratories Inc. and the firm's Chief Executive Officer, Jeffrey Bedard, to stop the distribution of unapproved and misbranded drugs, the Department of Justice announced today. Specifically, the complaint alleges that defend
7/28/17 - Doug Iliff: Figuring out health care costs
Someday in the next year or two, you might walk into the pharmacy, take your package of pills and drop your teeth at the price. That month of medicine which just cost you an additional $45 in copay might well have been $450 without insurance. On NPR the other day, a woman described paying $2 for every prescription in Europe.
7/28/17 - Dr Reddy`s out licenses phase-3 clinical trial drug to CHD Biosciences [Sudan Tribune]
Dr Reddy`s Laboratories Limited and CHD Bioscience Inc, a privately-held biopharmaceutical company, announced on Thursday, a global licensing agreement for the clinical development and commercialisation of Dr Reddy`s phase III clinical trial candidate, DFA-02. Under the terms of the agreement, Dr Reddy`s would receive equity in Colorado- based CHD
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415